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Introduction: Since 1991 until now, many radiosyntheses of [18F]FLT have been published. Most of them suffer
from side reactions and/or difﬁcult puriﬁcation related to the large amount of precursor necessary for the labeling
step. A fully automated synthesis using only commercial and unmodiﬁed materials with a reduced amount of
precursor would be desirable.
Methods: We ﬁrst explored the possibility to elute efﬁciently [18F]ﬂuorine from commercial and unmodiﬁed
cartridges with various amount of base. Based on these results, 10 mg and 5 mg of precursors were used for
the ﬂuorination step. The best conditions were transposed in an automated process for a one pot two steps
synthesis of labeled FLT.
Results: Using commercial and non-treated carbonate form of QMA cartridges, we were able to elute quantita-
tively the [18F]ﬂuorine with a very low amount of base (0.59 mg) and, with only 5 mg of precursor, to perform
an efﬁcient ﬂuorination reactionwith up to 94% incorporation of [18F]ﬂuorine. The synthesiswas fully automated
and radiochemical yields of 54% (decay corrected) were obtained within a synthesis time of 52 minutes.
Conclusion:We demonstrate that a fully automated and efﬁcient radiosynthesis of [18F]FLT is feasible with only
5 mg of precursor. Compare to the present state of the art, our method provides high yields of pure [18F]FLT
and is broadly adaptable to other synthesis automates.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
FLT (3′-deoxy-3′-ﬂuoro-thymidine)was initially developed as a thy-
midine analogue against HIV virus [1] after the success of 3′-azido-thy-
midine (AZT). Preliminary tests showed toxicity [2] at high doses
(100 mg/day over weeks) but incited its use at a tracer level (several
thousand folds less than the therapeutic dose). In 1991 [3] the ﬁrst
radiosynthesis of [18F]FLT and its potential use tomonitor drug distribu-
tion was described. Later on, Shields et al. [4] reported its use for imag-
ing proliferation in vivo by positron emission tomography.
Mechanisms of [18F]FLT uptake have been extensively studied; as a
pyrimidine analogue, [18F]FLT is transported into cells by passive diffu-
sion and active transporters (Na+ dependent carrier) to participate to
the salvage pathway in nucleosides synthesis and is further phosphory-
lated by the thymidine kinase 1 (TK1) leading to its accumulation insiderue du Loess, BP 28, F-67037
: +33 3 8810 62 73.
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e), frederic.boisson@iphc.cnrs.frthe cell [5,6]. The rationale behind its use to monitor cell proliferation is
based on the high TK1 activity in cancer cells; this activity reached its
maximum during the late G and S phases of cell duplication. However
after phosphorylation it was demonstrated that the radiolabeled [18F]
FLT did not signiﬁcantly incorporate in DNA as it acts as a terminating
nucleoside during DNA synthesis [6]. Despite its stability [18F]FLT is
eliminated by hepatobiliary pathway after glucuronidation [7].
Even if [18F]FLT exhibits lower uptake than [18F]FDG it has the ad-
vantage of being more speciﬁc and less sensitive to inﬂammation pro-
cess, it is considered as a good indicator of proliferation [8,9] and
received FDA agreement in 2009 for proliferation imaging andmonitor-
ing of responses to treatments [10–14]. However some authors showed
that the uptake did not always correlate with the proliferation index
[15,16]. The reasons involved are the difference of mechanisms that
can exist among the cancer cell lines (de novo versus salvage pathway),
the endogenous level of thymidine (especially in rodents) and the use of
some chemotherapy regimens [17–19]. In spite of these drawbacks [18F]
FLT can be used as a staging tool and tomonitor therapies if careful val-
idation is used.
The [18F]FLT attractiveness motivated the development of efﬁcient
radiosynthesis [20,21] and their automation; Fig. 1 summarizes the
main precursors (I–VII) used for the production of 18F-radiolabeled
FLT [22–26,29].
Fig. 1. [18F]FLT and the different precursors used in its radiosynthesis.
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sor VII [28,30], is to date the most used and is commercially available
at GMP grade.Table 1
Summary of [18F]FLT synthesis from 2003 to 2015.
[Ref.] Precursora (μmol/mg) Fluorination conditions
1 [27] IV (30/10) DMSO, 160 °C, 10′
2 [28] VII (40/33) 300 μL CH3CN, 110 °C, 5′
V (41/34) 300 μL CH3CN, 130 °C, 5′
3 [31] VII (48/40) 2 mL CH3CN, 150 °C, 100″
4 [32] VII (24/20) Tertiary alcohols 800 μL, 200 μL CH
5 [33] VII (6/5) 200 μL CH3CN, 200 μL IL, 120 °C, 15
VII (12/10)
6 [34] VII (40/33) CH3CN, 1 mL, 140 °C, 5′
7 [35] VII (24/20) t-BuOH 2 mL, 200 μL CH3CN, 100–1
VII (12/10)
VII (6/5)
8 [36] VII (9.6/8) 300 μL CH3CN, 100 °C, 5′
VII (22/18)
V (11/9)
9 [37] VII (24/20) 2 mL t-amylOH, 200 μL CH3CN, 120
10 [38] VII (36/30) 1 mL CH3CN
VII (18/15) 1 mL CH3CN
IV (30/25) 1 mL DMSO
11 [39] VII (6/5) t-amylOH 500 μL, 100 μL CH3CN, 1
12 [40] VII (12/10) 1 mL CH3CN, 100 °C, 5′
VII (18/15)
VII (24/20)
VII (30/25)
13 [41] VII (30/25) 2 mL CH3CN, 100 °C, 5′
t-amylOH = 2-methyl-butan-2-ol, t-BuOH = 2-methyl-propan-2-ol, TBAHCO3 = tetrabutyla
a Precursor see Fig. 1 (μmol/mg).
b Percentage of incorporation of [18F].
c Isolated yield of [18F]FLT (%, decay corrected).Different strategies have been published to achieve efﬁcient
radiosyntheses of [18F]FLT (Table 1). Most of the reported syntheses
are based on the use of a large amount of precursor (up to 40 mg)Base [18F]b [18F]FLTc
K2CO3 25 μmol, K222 15 mg 46 18
K2CO3 39.8 μmol, K222 28 mg 82 40
85 42
K2CO3 50 μmol, K222 22 mg 50 50
3CN, 110 °C, 10′ TBAHCO3 0.75 μmol ND 65
′ KHCO3 5 μmol 61 30
K2CO3 20 μmol 48 25
K2CO3 21.7 μmol, K222 10 mg ND 38
20 °C, 10′ TBAHCO3 0.75 μmol 85 60
53 ND
32 ND
K2CO3 10 μmol, K222 5 mg 64 27
76 ND
15 0.6
°C, 10′ TBAHCO3 0.75 μmol N85 64
K2CO3 22 μmol, K222 15 mg ND 40
25
18
20 °C, 15′ KHCO3 7.3 μmol 91 ND
TBAHCO3 75 μmol 27 ND
36 25
43 ND
58 39
TBAHCO3 37.5 μmol ND 39
mmonium hydrogen carbonate 0.075 M, K222 = Kryptoﬁx 2.2.2. ND not determined.
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purities (especially stavudine).
A survey of the literature shows that twomain approaches were de-
veloped; the ﬁrst one (entries 4, 5, 7 and 9 in Table 1) consisted in a var-
iation of the solvent with the use of ionic liquids or hindered tertiary
alcohols. The second strategy is based on a reduction of the amount of
base and the evaluation of the optimal precursor to base ratio (entries
8 and 11 in Table 1) to achieve high yields and to facilitate the puriﬁca-
tion by reduction of by-products [36,39].
The advantage of using a tertiary alcohol, to preserve the precursor
from elimination during the ﬂuorination step, was demonstrated and
under optimized conditions [18F]FLT was isolated in 65% yield (decay
corrected) on automated synthesizer using 20 mg (24 μmol) of precur-
sor VII [32].
When the amount of precursor was reduced to 10 mg (12 μmol) or
even 5 mg (6 μmol) a dramatic drop in the ﬂuorination yield was ob-
served. Only Lee et al. [39] (entry 11, Table 1) were successful in the
ﬂuorination of 5 mg of precursor VII using a low amount of base along
with t-amyl alcohol. The authors stated that the reduction of the
amount of base was only possible by the use of a modiﬁed QMA car-
tridge (preconditioned and elutedwith KOMs). Up to 91% incorporation
of 18F was observed but the complete synthesis (hydrolysis of the ﬂuo-
rinated intermediate and puriﬁcation) and its automation were not
performed.
In the frame of our research project on tumor radiotherapy fol-
low up by [18F]FLT preclinical PET imaging, concentrated formulat-
ed solution of [18F]FLT (above 500 MBq/mL) was necessary in order
to images 10 to 12mice a day and ensure a sufﬁcient dilution before
iv injection to lower the amount of ethanol injected. In a typical
batch the amount of ethanol reaches 10%, therefore a 200 μL injec-
tion of the formulated solution would result in an ethanol concen-
tration of almost 8 g per liter of blood (for a mouse of 25 g having
2 mL of blood). Moreover HPLC puriﬁcation would be amenable
to be sure to remove completely the stavudine (d4T) formed dur-
ing the synthesis. For these reasons we reinvestigated the [18F]
FLT radiosynthesis on a Raytest automated module to achieve a
high yield (and high radioactive concentration) with a low amount
of precursor to facilitate the puriﬁcation step.
Our strategy (Fig. 2) took advantages of the most efﬁcient
methods published so far (use of protic solvent and of low amount
of base) and involved an automated system with no or minor modi-
ﬁcations and with unmodiﬁed QMA cartridges along with a low
amount of precursor.Fig. 2. Radiosynthesis of [18F]FLT and2. Materials and methods
2.1. Chemicals, reagents and apparatus
(5′-O-DMTr-2′-deoxy-3′-O-nosyl-β-D-threo-pentofuranosyl)-3-N-
BOC-thymine, stavudine (d4T, 2′-3′-didehydro-2′-3′-dideoxythymidine)
and 3′-deoxy-3′-ﬂuoro-thymidine (FLT) were purchased from ABX.
K2CO3 99.99% and Kryptoﬁx K2.2.2 (4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo-[8.8.8]-hexacosane) were purchased from Aldrich.
Accell plus QMA carbonate light cartridges were obtained from ABX
or Waters and used as received.
Alumina N cartridges (Alox N, medium size) were purchased from
Macherey-Nagel and washed with 2 × 5 mL of pure water then dried
thoroughly before use.
[18O]H2O ([18O] N 97%) was purchased to Sercon.
Pure H20 (18.2 MΩ) was produced with a Purelab option Q puriﬁca-
tion system (Veolia®).
Anhydrous acetonitrile N99.8%, 3-methyl-pentan-3-ol 99%, ethanol
(absolute, HPLC grade), methanol (HPLC grade), ethyl acetate, hydro-
chloric acid, NaOH and sodium acetate were purchased from Aldrich
and used as received.
Sodium chloride 0.9% sterile solution was purchased from B BRAUN
medical.
Thin layer chromatographywas performed on aluminum back coat-
ed TLC silica gel 60F254 plates from Millipore.
HPLC Dionex®U3000 equipped with a DAD detector, a radioactivity
detector and a syncronis 250 × 4.6 mm (5 μm) analytical column was
used for quality control and speciﬁc activity determination.
Radio TLC reader miniGita (Raytest®)was used to determine 18F in-
corporation in manual ﬂuorination reactions.
Well counter: dose calibrator ISOMED 2010 was purchased from
Raytest.
Dry block heater: reacti-therm from Thermo Fisher Scientiﬁc® with
aluminum block and reacti-vap evaporator connected to nitrogen inlet
were used for water evaporation and to carry out manual ﬂuorination
reaction.
2.2. Manual synthesis
Manual syntheses were performed in 5 mL V-vials ﬁtted with hole
caps and teﬂon coated septa. A sample of 18F in water (10–50 MBq)
was transferred in a 1 mL syringe, counted in well counter and passed
through a QMA cartridge. The cartridge was dried with 5 mL of air andformation of stavudine (d4T).
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kryptoﬁx (acetonitrile/water) in a V-vial and counted for determination
of eluted activity. The azeotropic solution obtained by iterative addition
of acetonitrile (3 × 1mL)was evaporated in a dry block heater at 100 °C
under nitrogen ﬂow. The precursor (5 or 10 mg, solubilized in 750 μL of
3-methyl-pentan-3-ol and 250 μL of acetonitrile) was added and the
sealed vial was heated for 15 min at 110 °C. Samples (150 μL) were
withdrawn at 5, 10 and 15 min, diluted with methanol and water
(50 μL each) and spotted on TLC (eluted with ethyl acetate) for 18F in-
corporation determination using a minigita radio-TLC reader.
2.3. Automated synthesizer
A Raytest R&D synchrom® dual reactor was used for the
radiosynthesis with minor modiﬁcations. Only one reactor is used for
the synthesis, Al2O3 neutral cartridge was inserted between valve C1
and D4, outlet of the pump and vents were connected to gas bags to
avoid any radioactive releases in the hot cell ventilation system, 3 addi-
tional valves (G3-G5) and a 20 mL vial were added to measure the 18F
activity transferred from the target (red rectangle on Fig. 3). The system
is equipped with a semi preparative HPLC (Knauer) including an
isocratic pump, a 254 nm ﬁxed wavelength UV detector, a radioactivity
detector and a 5 mL stainless steel injection loop. Puriﬁcation was done
on a syncronis 250 × 10 mm (5 μm) semi-preparative column at 3 mL/
min.
According to the above diagram, the following workﬂow was used
for automated [18F]FLT production using 5 mg or 10 mg of precursor.
Step 1: Nucleophilic ﬂuorination
(i) [18F]Fluorine from target vial transferred through a QMA car-
tridge on the module and water recovered in 10 mL V-vial.
(ii) [18F]Fluorine eluted into reactor 1 with 12–15 mg of K222,
0.59 mg of K2CO3 in 800 μL of acetonitrile and 380 μL of water
(SC1).
(iii) [18F]KF dried under reduced pressure and Argon ﬂow at 90 °C
with successive addition of acetonitrile (SC2, 1.7 mL).Fig. 3. Synchrom R&D layout(iv) The precursor 3-N-Boc-5′-O-dimethoxytrityl-3′-O-nosyl-
thymidine (5 mg) dissolved in 250 μL of acetonitrile and
750 μL of 3-methyl-pentan-3-ol (SC3) is added into the reactor.
(v) Fluorination is carried out at 110–112 °C during 15 min.
Step 2: Acidic hydrolysis
(i) The reactor is cooled down to 80 °C.
(ii) The solvents are evaporated under reduced pressure and argon
ﬂow.
(iii) 250 μL of acetonitrile (SC5) is added to the reactor.
(iv) 1 mL of HCl 1 M (SC4) added to the reactor.
(v) Reactor heated at 90 °C during 10min. The pale yellow/colorless
solution turns to orange progressively (formation of the
dimethoxytrityl cation).
Step 3: Neutralization
(i) Reactor cooled down to 60 °C.
(ii) Addition of NaOH 1 N/AcONa 0.25 M (1.2 mL) and 2.85 mL of
H2O (SC6).
Step 4: HPLC puriﬁcation
(i) Reactionmixture transferred to theHPLC loop (5mL) via anAlox
neutral cartridge.
(ii) Puriﬁcation of the crude mixture by HPLC semi-preparative at
3 mL/min. Using 0.9% NaCl/EtOH (92/8 v/v).
(iii) [18F]FLT eluted at Rt = 24min and collected in a vial or in reac-
tor 2 (average collected volume 7.5 mL).
(iv) HPLC eluent changed (manually) to MeOH/CH3CN/H2O 20/20/
60 to clean the column.
2.4. Production of [18F]F−
An ACSI 24 MeV® cyclotron was used for 18F production on a small
volume target. Irradiation of [18O]H2O (1 mL) was performed at
16.5 MeV, 30 μA during 15 min to produce a typical dose of 19 GBq
(EOB). After 5 min of cooling the radioactivity is transferred to the hot
cell under He pressure and the target is rinsed twice (2 × 1 mL) with
pure water. Total transferred activity is counted (well counter) and
sent into the Raytest module under He pressure. Residual activity infor [18F]FLT production.
524 P. Marchand et al. / Nuclear Medicine and Biology 43 (2016) 520–527the intermediate vial after transfer is counted. Starting from 19 GBq
(EOB), 16 GBqwas transferred to the synthesizer for [18F]FLT synthesis.
2.5. Quality control and speciﬁc activity determination for preclinical use
Puriﬁed [18F]FLT was injected on analytical HPLC (25 μL) for deter-
mination of chemical and radiochemical purities. A second injection
with the non-radioactive authentic reference FLT (3′-deoxy-3′-ﬂuoro-
thymidine)was done to assay the identity of the radioactive compound.
The column was eluted with a gradient of acetonitrile in water (H2O/
CH3CN 90/10 to 80/20 over 10 min then 80/20 to 70/30 over 15 min.)
at 0.7 mL/min and UV detection was performed at 265 nm.
The speciﬁc activity was determined by injection on analytical HPLC
of a known radioactive dose of [18F]FLT (0.7 to 1.5MBq) and quantiﬁca-
tion of the amount of FLT by reporting theUV signal area on a calibration
curve (R2 = 0.999).
The pH of the solutionwas determined by applying a drop of the pu-
riﬁed solution onto a pH indicator strip and comparing the result with
the provided scale.
The volumic activity (MBq/mL) at the end of synthesis was deter-
mined by measuring the activity of a known volume of puriﬁed [18F]
FLT (25 to 50 μL).
3. Results and discussion
3.1. Manual synthesis, QMA elution
During the synthesis of [18F]FLT, one main problem encountered is
the base mediated elimination of the nosylate, leading to the formation
of the stavudine and consuming the precursor. Suehiro et al. [36] inves-
tigated carefully the inﬂuence of the base amount and highlighted the
importance of the precursor to base ratio on the 18F ﬂuorine incorpora-
tion during the labeling step. Our ﬁrst approach to minimize the forma-
tion of stavudine was to reduce the amount of base used during the
elution of the QMA cartridge. Using commercially available and untreat-
ed (used as received) QMA cartridges under carbonate form we were
able to elute more than 95% of the radioactivity with low amount of
K2CO3. Typically, 10 to 50 MBq of [18F]ﬂuorine was adsorbed on QMA
cartridges and eluted with a mixture of CH3CN (800 μL) and water
(270 μL) containing 12–15 mg of K222 and various amount of K2CO3.
From 1 mg down to 0.63 mg (7.2 to 4.6 μmol) of K2CO3 in 270 μL ofFig. 4. Example of radio TLC obtained with 10 mg of precursorwater the radioactivity was almost quantitatively eluted (more than
95% recovery of activity); with lower amount (0.59 mg, 4.3 μmol) only
80% of radioactivity was recovered in these conditions. However using
a larger amount of water (380 to 400 μL) the QMA was fully eluted
(N95%) with as low as 4.3 μmol (0.59 mg) of K2CO3 in presence of K222
(12–14 mg in 800 μL of CH3CN).
3.2. Manual synthesis, determination of 18F incorporation
The following step of our evaluation was to perform the
radioﬂuorination of precursor VII under various conditions (amount of
precursor and base). The solutions eluted from QMA cartridges (see
3.1) were evaporated under N2 ﬂow at 100 °C with iterative addition
of CH3CN (3 × 1 mL). After drying, the precursor 5 or 10 mg in 1 mL of
solvent (3-methyl-pentan-3-ol/CH3CN 75/25) was added and the vial
was heated for 15 min at 110 °C. Samples were withdrawn at 5, 10,
and 15 min, diluted and analyzed by radio-TLC (eluted with 100%
ethyl acetate, Fig. 4). The precursor to base ratio (P/B in Fig. 5) was crit-
ical to achieve high incorporation of the 18F ﬂuorine (Fig. 5). No signiﬁ-
cant difference in conversion was observed between 10 and 15 min.
Better resultswere obtainedwhen the precursor to base ratiowas supe-
rior to 1.3; using such conditions 97% and 93% conversions were ob-
served using 10 mg and 5 mg of precursor respectively. Although
these results represent the higher incorporation percentages reported
so far, it isworth to note that they reﬂect only the composition of the liq-
uid phase, the radioactivity in solution usually represents 90–95% of the
initial amount introduced in the vial (part of it get stuck on the glass
wall of the V-vial). We were not able to identify a parameter that
could inﬂuence positively or negatively this amount of lost radioactivity.
One reason might come from the manual drying step that led to some
ﬂuctuating binding of 18F ﬂuorine on the glassware.
3.3. Automated synthesis
The above mentioned results prompted us to adapt themanual syn-
thesis on our Raytest automate. We ﬁrst adapted the conditions using
10mg of precursor along with 1 mg of K2CO3. As the reactor of the syn-
thesizer is suitable for reaction volumes of 1 mL no dilution was neces-
sary and the concentration of the precursor could be kept the same as in
manual synthesis. Classical automated sequence was used to transfer
the radioactivity into the reactor and to dry the [18F]-KF. The, 1 mg of K2CO3 and 13 mg of K222 at 110 °C after 10 min.
Fig. 5. 18F incorporation over time using various amounts of base and precursor. Reactions carried out at 110 °C in 1 mL of solvent (3-methyl-pentan-3-ol/CH3CN 75/25). P/B: Precursor
(μmol)/Base (μmol).
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precursor dissolved in acetonitrile and 3-metyl-pentan-3-ol. Hindered
alcohols are now often used in FLT synthesis to reduce the formation
of by-products especially when they are generated by the competitive
elimination reaction [32]. Among the potential hindered alcohols we
choose 3-methyl-pentan-3-ol for its 123 °C boiling point; in such condi-
tions the reaction can be performed at high temperaturewithout gener-
ating an excessive pressure in the reactor. During our synthesis the
maximum pressure observed never exceeded 230 KPa (2.3 bars). The
other advantage is the easy elimination of the alcohol under reduced
pressure, this evaporation step is mandatory as otherwise theFig. 6.HPLC chromatogram of crude [18F]FLT during puriﬁcation step on synthesizer. Top: UV de
beginning of the synthesis, black arrow on radioactive channel denotes the injection time on sdeprotection step using 1 M aqueous HCl fails due to the non-
miscibility of the reagents (deprotection using other acid, ie
CF3CO2H was not attempted).
The ﬂuorinations was carried out at 110–112 °C during 15 min
and after evaporation 250 μL of acetonitrile was added to the reactor
to facilitate the solubilization of the intermediate during the
deprotection step. In our classical set-up, CH3CN and HCl are located
in separated solvent containers (SC4 and SC5) but a mixture of
CH3CN and aqueous HCl can also be used in a single solvent contain-
er. Addition of a larger volume of CH3CN considerably impaired the
ﬁnal HPLC puriﬁcation.tector. Bottom: radioactive detector. X axis represents time from start of themodule at the
emi-preparative HPLC.
Table 2
Comparison of decay corrected yields of [18F]FLT.
Ref. Precursora Precursor mg Fluorination % [18F]FLT % (DC)
[33] 12 μmol 10 mg 48 25
[35] 12 μmol 10 mg 53 ND
[40] 12 μmol 10 mg 27 ND
Our Work 12 μmol 10 mg 97 56
[36] 11 μmol 9.2 mg 15 0.6
[36] 9.6 μmol 8 mg 64 27
[33] 6 μmol 5 mg 61 30
[35] 6 μmol 5 mg 32 ND
[39] 6 μmol 5 mg 91 ND
Our Work 6 μmol 5 mg 93 54
a All entries refer to the same precursor (VII, 5′-O-DMTr-2′-deoxy-3′-O-nosyl-β-D-threo-
pentofuranosyl-3-N-BOC-thymine) except entry 5, Ref. [36] using 11 μmol (9.2 mg) of pre-
cursor V, 5′-O-DMTr-2′-deoxy-3′-O-nosyl-β-D-threo-pentofuranosyl-thymine.
526 P. Marchand et al. / Nuclear Medicine and Biology 43 (2016) 520–527Deprotectionwas carried out at 90 °C during 10min, the reactorwas
cooled down and the reaction was neutralized using NaOH 1 N with
0.25 M CH3CO2Na. The crude product was then passed through an alu-
mina neutral cartridge and directly sent into the HPLC loop for semi-
preparative puriﬁcation on a syncronis column. Pure [18F]FLT was col-
lected at 24 min (Fig. 6, chromatogram of semi-preparative HPLC)
after injection and ready to use (already formulated in NaCl 0.9% with
8% ethanol), the average yield (decay corrected) was 56% (±5%, n =
5). Starting from 16 GBq we obtained a ready to inject solution of
7.5 mL with a [18F]FLT concentration greater than 500 MBq/mL. The
synthesis time was 52 min without puriﬁcation and 81 min from start
of synthesis to the ﬁnal collect of the puriﬁed product (HPLC included).
With 5 mg of precursor the automated synthesis required only
minor modiﬁcations; the QMA cartridge is eluted with a solution con-
taining 12–14 mg of K222, 0.59 mg of K2CO3 in 800 μL of CH3CN and
380 μL of H2O. As the amount of water eluted from QMA was moreFig. 7.HPLC chromatograms of puriﬁed [18F]FLT. Top: radioactive channel. Middle: UV channel
condition Stavudine (d4T) has a retention time of 9.1 min.important, 1 min of drying was added to the sequence. The remaining
of the synthesis remained unchanged. Using such a low amount of pre-
cursor, [18F]FLT was obtained after puriﬁcation in 54% (n= 4, min. 45%
max. 60%) decay corrected yield.
Only few percent of yield difference were observed during our syn-
thesis when 5 mg was used instead of 10 mg. When compared to re-
cently published radiosynthesis using 10 mg or even 5 mg of
precursor (Table 2) our automated synthesis achieved high yields of
pure [18F]FLT.
3.4. Quality control and speciﬁc activity.
A quality control for pre-clinical use was performed. The results
demonstrated a chemical and radiochemical purity above 95% (Fig. 7)
and co-injection of authentic FLT proved the identity of the produced
[18F]FLT (Rt = 12.4 min).
The pH of the solution ranged from 6 to 7 and the volumic activity
was superior to 500 MBq/mL for each batch (n = 9) with a speciﬁc ac-
tivity of 35 to 72 GBq/μmol.
No stavudine could be detected by HPLC in the ﬁnal product (Rt =
9.1 min for the stavudine under same analytical conditions).
4. Conclusion
Combining a low amount of base and hindered alcohol as solvent,
we synthesized [18F]FLT in high yield (up to 60%) on an automated
module. The one pot, two steps, radiosynthesis can be carried out on
any single reactor synthesizer without any modiﬁcation and using
only commercially and unmodiﬁed materials. Under such conditions,
as low as 5 mg of precursor can be used facilitating the puriﬁcation
step. The synthesis took 52min and after semi-preparative HPLC puriﬁ-
cation [18F]FLT is obtained in a ready to inject solution for preclinical265 nm. Bottom UV channel 265 nm co-injected with authentic FLT reference. In the same
527P. Marchand et al. / Nuclear Medicine and Biology 43 (2016) 520–527imaging. The volumic activity was greater than 500 MBq/mL for every
batch enabling the use of the solution during 4 h for preclinical imaging
and ensuring a low amount of ethanol injected. The method seems
highly suitable for other base sensitive compounds prone to fast elimi-
nation reaction.
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